Korean-Developed Humanized Mouse Model Exported to UK for Antibody Therapy Research

Dong-A Ilbo highlights a significant achievement for South Korea's biotechnology sector: GEMCRO's successful export of its proprietary hiFcRn™ humanized mouse model to the United Kingdom. This event is particularly noteworthy as it represents the first time a preclinical animal model developed in Korea has been directly integrated into foreign new drug development research. The hiFcRn™ model, designed to accurately simulate the human FcRn (neonatal Fc receptor) system, is crucial for evaluating the efficacy and pharmacokinetic properties of antibody-based therapeutics, offering a more clinically relevant prediction than previous models. GEMCRO's expertise in gene editing technologies like CRISPR/Cas9 and its robust supply chain for frozen sperm and embryos underscore its advanced capabilities. This export not only validates GEMCRO's technical prowess but also positions South Korea as a key player in the global preclinical research market. The company's ambition to expand into European and North American markets following this success signals a promising future for Korean biotech innovation on the international stage.

“

This export is significant in that a preclinical animal model developed in Korea has been directly incorporated into the global new drug development pipeline.